Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.42
VRTX's Cash to Debt is ranked lower than
75% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. VRTX: 1.42 )
Ranked among companies with meaningful Cash to Debt only.
VRTX' s 10-Year Cash to Debt Range
Min: 0.92  Med: 2.27 Max: 26.61
Current: 1.42
0.92
26.61
Equity to Asset 0.45
VRTX's Equity to Asset is ranked lower than
74% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. VRTX: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
VRTX' s 10-Year Equity to Asset Range
Min: -0.02  Med: 0.50 Max: 0.95
Current: 0.45
-0.02
0.95
F-Score: 3
Z-Score: 13.28
M-Score: -1.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -108.02
VRTX's Operating margin (%) is ranked lower than
55% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. VRTX: -108.02 )
Ranked among companies with meaningful Operating margin (%) only.
VRTX' s 10-Year Operating margin (%) Range
Min: -602.63  Med: -127.43 Max: 8.07
Current: -108.02
-602.63
8.07
Net-margin (%) -117.36
VRTX's Net-margin (%) is ranked lower than
58% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. VRTX: -117.36 )
Ranked among companies with meaningful Net-margin (%) only.
VRTX' s 10-Year Net-margin (%) Range
Min: -630.27  Med: -114.19 Max: 2.1
Current: -117.36
-630.27
2.1
ROE (%) -62.80
VRTX's ROE (%) is ranked lower than
70% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. VRTX: -62.80 )
Ranked among companies with meaningful ROE (%) only.
VRTX' s 10-Year ROE (%) Range
Min: -180.27  Med: -37.78 Max: 4.58
Current: -62.8
-180.27
4.58
ROA (%) -31.40
VRTX's ROA (%) is ranked lower than
55% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. VRTX: -31.40 )
Ranked among companies with meaningful ROA (%) only.
VRTX' s 10-Year ROA (%) Range
Min: -58.14  Med: -25.55 Max: 1.51
Current: -31.4
-58.14
1.51
ROC (Joel Greenblatt) (%) -90.05
VRTX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. VRTX: -90.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1092.55  Med: -167.78 Max: 96.25
Current: -90.05
-1092.55
96.25
Revenue Growth (3Y)(%) -28.50
VRTX's Revenue Growth (3Y)(%) is ranked lower than
74% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. VRTX: -28.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VRTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -32.4  Med: 8.10 Max: 130.2
Current: -28.5
-32.4
130.2
» VRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

VRTX Guru Trades in Q3 2014

Stanley Druckenmiller 146,600 sh (New)
Paul Tudor Jones 7,726 sh (+254.73%)
Pioneer Investments 661,813 sh (unchged)
Vanguard Health Care Fund 11,807,500 sh (unchged)
Ken Fisher 4,593 sh (-31.99%)
Steven Cohen 443,300 sh (-52.57%)
» More
Q4 2014

VRTX Guru Trades in Q4 2014

Andreas Halvorsen 764,200 sh (New)
Stanley Druckenmiller Sold Out
Pioneer Investments 647,257 sh (-2.20%)
Ken Fisher 4,378 sh (-4.68%)
Paul Tudor Jones 6,589 sh (-14.72%)
Vanguard Health Care Fund 9,808,860 sh (-16.93%)
Steven Cohen 16,500 sh (-96.28%)
» More
Q1 2015

VRTX Guru Trades in Q1 2015

Lee Ainslie 524,867 sh (New)
Jim Simons 159,317 sh (New)
George Soros 56,912 sh (New)
Louis Moore Bacon 97,500 sh (New)
Andreas Halvorsen 1,770,150 sh (+131.63%)
Steven Cohen 29,200 sh (+76.97%)
Pioneer Investments 794,247 sh (+22.71%)
Ken Fisher 4,386 sh (+0.18%)
Paul Tudor Jones Sold Out
Vanguard Health Care Fund 9,533,911 sh (-2.80%)
» More
Q2 2015

VRTX Guru Trades in Q2 2015

Vanguard Health Care Fund 9,533,911 sh (unchged)
Ken Fisher 4,378 sh (-0.18%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 32.47
VRTX's Forward P/E is ranked lower than
60% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. VRTX: 32.47 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 33.23
VRTX's P/B is ranked lower than
95% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. VRTX: 33.23 )
Ranked among companies with meaningful P/B only.
VRTX' s 10-Year P/B Range
Min: 5.79  Med: 12.32 Max: 37
Current: 33.23
5.79
37
P/S 52.86
VRTX's P/S is ranked lower than
79% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. VRTX: 52.86 )
Ranked among companies with meaningful P/S only.
VRTX' s 10-Year P/S Range
Min: 4.47  Med: 18.86 Max: 80.48
Current: 52.86
4.47
80.48
EV-to-EBIT -49.36
VRTX's EV-to-EBIT is ranked lower than
475% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. VRTX: -49.36 )
Ranked among companies with meaningful EV-to-EBIT only.
VRTX' s 10-Year EV-to-EBIT Range
Min: -49.5  Med: -10.60 Max: 4164.9
Current: -49.36
-49.5
4164.9
Current Ratio 4.49
VRTX's Current Ratio is ranked higher than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. VRTX: 4.49 )
Ranked among companies with meaningful Current Ratio only.
VRTX' s 10-Year Current Ratio Range
Min: 1.73  Med: 4.50 Max: 30.95
Current: 4.49
1.73
30.95
Quick Ratio 4.38
VRTX's Quick Ratio is ranked higher than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. VRTX: 4.38 )
Ranked among companies with meaningful Quick Ratio only.
VRTX' s 10-Year Quick Ratio Range
Min: 1.62  Med: 4.50 Max: 30.95
Current: 4.38
1.62
30.95
Days Inventory 132.49
VRTX's Days Inventory is ranked lower than
55% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. VRTX: 132.49 )
Ranked among companies with meaningful Days Inventory only.
VRTX' s 10-Year Days Inventory Range
Min: 62.49  Med: 113.91 Max: 254.87
Current: 132.49
62.49
254.87
Days Sales Outstanding 48.83
VRTX's Days Sales Outstanding is ranked higher than
64% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. VRTX: 48.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRTX' s 10-Year Days Sales Outstanding Range
Min: 25.75  Med: 47.06 Max: 106.15
Current: 48.83
25.75
106.15

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 193.52
VRTX's Price/Net Current Asset Value is ranked lower than
98% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. VRTX: 193.52 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VRTX' s 10-Year Price/Net Current Asset Value Range
Min: 2.35  Med: 12.94 Max: 1835.5
Current: 193.52
2.35
1835.5
Price/Tangible Book 36.12
VRTX's Price/Tangible Book is ranked lower than
94% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. VRTX: 36.12 )
Ranked among companies with meaningful Price/Tangible Book only.
VRTX' s 10-Year Price/Tangible Book Range
Min: 2.13  Med: 9.81 Max: 122.26
Current: 36.12
2.13
122.26
Price/Median PS Value 2.84
VRTX's Price/Median PS Value is ranked lower than
81% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. VRTX: 2.84 )
Ranked among companies with meaningful Price/Median PS Value only.
VRTX' s 10-Year Price/Median PS Value Range
Min: 0.27  Med: 1.09 Max: 4.02
Current: 2.84
0.27
4.02
Earnings Yield (Greenblatt) (%) -2.02
VRTX's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. VRTX: -2.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VRTX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.4  Med: 3.70 Max: 5.3
Current: -2.02
1.4
5.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VX1.Germany, VRTX.Mexico, 0QZU.UK,
Vertex Pharmaceuticals Inc was incorporated in 1989. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. It is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and early-stage development programs. The Company has marketed KALYDECO (ivacaftor) since it was approved in 2012 for the treatment of certain patients with CF and is seeking approval to market lumacaftor in combination with ivacaftor in order to increase the number of patients with CF who would be eligible for treatment with the Company's drugs. It is engaged in a number of other research and early-stage development programs, including programs in the areas of oncology and neurology. The Company's two products are INCIVE (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus, or HCV, infection; and KALYDEC (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis, or CF, who genetic mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. As the Company markets and sells its approved products and advances its drug candidates through clinical development toward commercialization, it continues to build and maintain its supply chain and quality assurance resources. It faces competition based on the safety and efficacy of its products and drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. Its registered trademarks include Vertex, KALYDECO and INCIVEK. The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, safety monitoring, record keeping, promotion, advertising, distribution and marketing of its products and drug candidates are subject to extensive regulation by United States and foreign governmental authorities.
» More Articles for VRTX

Headlines

Articles On GuruFocus.com
Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 

More From Other Websites
Biogen Can Get Growth Spurt It Needs With Vertex Deal: Real M&A Jul 30 2015
Vertex Pharmaceuticals (VRTX) Earnings Report: Q2 2015 Conference Call Transcript Jul 30 2015
Vertex Posts Wider Y/Y Loss but Raises Kalydeco Outlook - Analyst Blog Jul 30 2015
Large-Cap Healthcare Stocks Outperform Small Caps Jul 30 2015
Edited Transcript of VRTX earnings conference call or presentation 29-Jul-15 9:00pm GMT Jul 30 2015
Vertex Reports Second Quarter 2015 Financial Results Jul 29 2015
[$$] Vertex Revenue Rises 20% Jul 29 2015
VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 29 2015
4:17 pm Vertex Pharma beats by $0.04, beats on revs; raises FY15 rev guidance for KALYDECO,... Jul 29 2015
Vertex reports 2Q loss Jul 29 2015
Vertex reports 2Q loss Jul 29 2015
Vertex Reports Second Quarter 2015 Financial Results Jul 29 2015
Q2 2015 Vertex Pharmaceuticals Inc Earnings Release - After Market Close Jul 29 2015
Will Vertex (VRTX) Surprise with a Lower Loss in Q2? - Analyst Blog Jul 28 2015
CRBP: Warrant Exercise To Provide Sufficient Cash Through 2016 Jul 28 2015
What to Watch in the Week Ahead and on Monday, July 27 Jul 24 2015
Will The High Cost Of Vertex's New Cystic Fibrosis Drug Push The U.S. To European Style Pricing? Jul 22 2015
How High? The Backlash Over Rising Prescription Drug Prices Gains Steam Jul 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK